Effectiveness of Lactobacillus Paracasei LPB27 Probiotic in Treating Eczema in Children Aged 3 Months to 3 Years

What this Trial Is About

This research aims to evaluate the effectiveness of the probiotic Lactobacillus paracasei LPB27 in treating eczema in young children aged 3 months to 3 years. Childhood eczema is a common, chronic skin condition causing dry skin and itching, which significantly affects quality of life. The study explores whether oral probiotics can improve gut microbiome composition and thereby benefit eczema symptoms and overall well-being. Participants will receive either Lactobacillus paracasei LPB27 at a dose of 10 billion colony-forming units per day or a placebo containing maltodextrin. Both treatments are administered orally once daily for 12 weeks, mixed with breast milk, formula, or solid food. The trial is randomized, double-blind, and placebo-controlled to compare the probiotic against the placebo effectively. During the 12-week study, children will be monitored for treatment success based on symptom improvement. Researchers will assess changes in eczema severity using various validated scores, track the use of rescue medications, and evaluate changes in gut and skin microbiota. Safety and adherence will be observed throughout the study, with the main outcome measured at 12 weeks after starting treatment.

LaCE (Lactobacillus Paracasei LPB27 On Early Childhood Eczema)